This is a working overview of LKKTETQ, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-01 and is reviewed periodically as new material appears.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
=== Adaptive immunity === Activated platelets are able to participate in adaptive immunity, interacting with antibodies. They are able to specifically bind IgG through FcγRIIA, a receptor for IgG's constant fragment (Fc). When activated and bound to IgG-opsonised bacteria, platelets release reactive oxygen species (ROS), antimicrobial peptides, defensins, kinocidins and proteases, killing the bacteria directly. Platelets also secrete proinflammatory and procoagulant mediators such as inorganic polyphosphates or platelet factor 4 (PF4), connecting innate and adaptive immune responses.
=== Cleaning === • surface (suction cleaning by vacuum) • wet (cleaning with water or water plus detergent) • dry (cleaning with organic solvents) • spotting (treating of localized stains with wet or dry-cleaning solvents) Wet, dry, and spotting treatments should always be conducted by professionals. Vacuum maintenance of materials in open exhibit, textiles being returned to storage, and newly accessioned textiles before they are displayed or stored is best practice. Aqueous cleaning of archaeological textiles achieves "relaxation of folds and removal of surface dirt without causing further weakening of the object.”
=== Early studies === The first direct examination of the shroud by a scientific team was undertaken in 1969–1973 in order to advise on preservation of the shroud and determine specific testing methods. This led to the appointment of an 11-member Turin Commission to advise on the preservation of the relic and on specific testing. Five of the commission members were scientists, and preliminary studies of samples of the fabric were conducted in 1973. In 1976 the physicist John P. Jackson, the thermodynamicist Eric Jumper and the photographer William Mottern used image analysis technologies developed in aerospace science for analyzing the images of the Shroud. In 1977 these three scientists and over thirty other experts in various fields formed the Shroud of Turin Research Project. In 1978 this group, often called STURP, was given direct access to the Shroud. Joe Nickell of the Committee for Skeptical Inquiry has pointed out that "STURP's leaders served on the executive council of the Holy Shroud Guild, which is devoted to the "cause" of the reputed relic", a group whose motivation it was to campaign for the legitimacy of the Turin shroud. Paleontologist Steven Schafersman has described STURP as "an organization totally composed of believers in the authenticity of the Shroud", with the exception of a single agnostic being Walter McCrone. Also in 1978, independently from the STURP research, Giovanni Tamburelli obtained at CSELT a 3D-elaboration from the Shroud with higher resolution than Jumper and Mottern.
Sources: en.wikipedia.org
The Hukbong Bayan Laban sa Hapon (lit. 'People's Army Against the Japanese'), better known by the abbreviation Hukbalahap, was a Filipino communist guerrilla movement formed by the farmers of Central Luzon. They were originally formed to fight the Japanese, but extended their fight into a rebellion against the Philippine government, known as the Hukbalahap rebellion in 1946. It was eventually put down through a series of reforms and military victories by Defense Secretary, and later President, Ramon Magsaysay. Constituted in March 1942, the Hukbalahap was to be part of a broad united front resistance to the Japanese occupation of the Philippines. This original intent is reflected in its name. By 1950, the Communist Party of the Philippines (PKP) had resolved to reconstitute the organization as the armed wing of a revolutionary party, prompting a change in the official name to Hukbong Mapagpalaya ng Bayan, likely in emulation of the Chinese People's Liberation Army. Notwithstanding this name change, the HMB continued to be popularly known as the Hukbalahap, and the English-speaking press continued to refer to it and its members, interchangeably, as the Huks (Singular: Huk) during the whole period between 1945 and 1952. A monument dedicated to the Huks in Cabiao, Nueva Ecija, was constructed to honor their actions during World War II. On October 14, 2023, the Luis M.
=== Iodothyronine deiodinase === Central to human (and vertebrate in general) thyroid hormone metabolism are three iodothyronine deiodinases, with gene symbols DIO1, DIO2, DIO3 in humans. Related proteins have been found in invertebrate chordates, mostly with a selenocystine, though a few have cystine instead.
The legal status of psychedelic drugs in United States varies depending on the specific drug and jurisdiction in question. Various major psychedelics, including DMT, psilocin, psilocybin, 5-MeO-DMT, mescaline, DOM, 2C-B, 25I-NBOMe, MDA, and LSD among others, are explicitly controlled substances. In addition, if intended for human consumption and "substantially similar", many psychedelics that are analogues of scheduled psychedelics may themselves also be considered controlled substances. The Controlled Substances Act (CSA) and U.S. Drug Enforcement Administration (DEA) regulate the legality of psychedelic drugs in the United States. Almost all controlled psychedelic drugs in the country are Schedule I controlled substances as of 2026, with a few exceptions.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.